Author: admin

Kevin Coffey & Christina Keller With A Brighter Future Interviewed On The Influential Entrepreneurs Podcast, Discussing Devastating Emotional Consequences Of Foreclosure

Kevin Coffey & Christina Keller discuss the emotional challenges homeowners can experience when facing foreclosure or falling behind on mortgage payments.

Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-kevin-coffey-christina-keller-with-a-brighter-future-discussing-the-devastating-emotional-consequences-of-foreclosure/

Foreclosure can have devastating emotional consequences that extend beyond just the financial aspect. As discussed in the podcast episode, one of the primary emotional effects of foreclosure is embarrassment. Due to the stigma associated with losing your home, individuals facing foreclosure may feel isolated and withdrawn from their community. This embarrassment can lead to a sense of shame and depression and can be as devastating as losing a loved one.

Additionally, foreclosure can strain relationships, as discussed in this episode. The blame game may arise within families, with individuals pointing fingers at each other for the financial difficulties that led to foreclosure. This strain on relationships can further isolate individuals and create a sense of division within the family unit, adding to the emotional burden of the foreclosure process.

Kevin and Christina’s innovative solutions are not just about financial relief but also about providing emotional support during challenging times. Whether you want to stay in your home or delay foreclosure, they can help guide you through the process. Their unique program, “More Money For You,” offers a remarkable opportunity to maximize your earnings compared to selling your home “as is.” By partnering with Kevin and Christina, you can put more money into your pocket and receive invaluable assistance in alleviating the emotional distress and financial strain associated with the prospect of losing your home.

Kevin & Christina said: “Many studies have shown that stress can cause people to have physical and emotional problems. We’re trying to give homeowners options so that they can have a brighter future.”


Video Link: https://www.youtube.com/embed/MfNa3aekFFw

About Kevin Coffey and Christina Keller

Kevin and Christina are a couple of Colorado folks who know what it’s like when things get tough. Kevin grew up in North Denver, and Christina in Thornton. Kevin’s family faced the heartbreaking reality of foreclosure when he was younger. He watched as their home, filled with love and laughter, slipped away. Looking back, he wishes his family had been thrown a lifeline that offered choices like A Brighter Future now provides homeowners. Kevin and Christina are not just another option; they’re a lifeline, a bridge to a brighter future.

Learn More: http://www.abrighter-future.com

Recent news and interviews:

  • Kevin Coffey and Christina Keller Discussing Their ‘More Money for You’ Program: 

https://authoritypresswire.com/kevin-coffey-christina-keller-with-a-brighter-future-were-interviewed-on-the-influential-entrepreneurs-podcast-discussing-their-more-money-for-you-program/ 

  • Kevin Coffey and Christina Keller Discussing How to Prevent a House From Going Into Foreclosure:

https://authoritypresswire.com/kevin-coffey-christina-keller-with-a-brighter-future-interviewed-on-podcast-discussing-how-to-prevent-a-house-from-going-into-foreclosure/

  • Kevin Coffey and Christina Keller Discussing Understanding The Foreclosure Process: 

https://authoritypresswire.com/kevin-coffey-christina-keller-with-a-brighter-future-interviewed-on-the-influential-entrepreneurs-podcast-discussing-understanding-the-foreclosure-process/ 

Be advised that A Brighter Future LLC. provides general information and resources for informational purposes only. We are not providing legal advice or investment advice, and nothing on our platform or in our communications should be construed as such. Our materials, including but not limited to articles, guides, and responses to inquiries, are not a substitute for professional legal or investment advice from qualified professionals licensed in your jurisdiction. If you require legal advice, investment advice, or representation, we strongly recommend consulting with licensed professionals who can provide tailored advice based on your specific circumstances. While we strive to ensure the accuracy of the information provided, laws, regulations, and market conditions vary and may change over time. Therefore, we cannot guarantee the completeness or accuracy of the information presented.

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

The Growing Demand for Professional Appliance Repair Services: Quebec

Over the past years, professional services in appliance repair all over Quebec have shown quite real growth. Several factors can account for this increase: market trends and expectation shifts from customers to specialized services, such as emergency fridge repair solutions. But what explains the significant rise in this demand?

Market Trends That Drive Demand

Several market trends drive demand for professional appliance repair services in Quebec:

Longer Life of Appliances: The newer appliances have a longer useful life. For this, they would require constant servicing and occasional repairs to be kept in good working condition. Homeowners are promised to invest more in professional repair services to prolong the life of appliances rather than replace them.

Environmental Concerns: People are becoming increasingly environment-conscious. Hence, in case of failure of any appliances, consumers prefer to get them repaired rather than replace them. This is an eco-friendly way by which acres of landfills can be saved and resources can be conserved; it has increased the demand for professional repair services.

Technological Advancements: The fancier and, more importantly, technological they become, appliances do require specialized knowledge in repairs. Professional technicians with expertise in the most updated technologies are called in highly to tackle these complex issues.

For more detailed information about appliance repair market trends, visit Forbes.

Evolving Customer Expectations

With a change in customer expectations, the demand for professional appliance repair services also changes. Today’s consumers expect:

Quick Response Times: In the event of an appliance failure, essential items like refrigerators, require fast and confident service. Studying emergency fridge repair solutions is readily important in servicing such urgent needs and avoiding food wastage.

High-Quality Service: The customers expect quality in the repairs, which shall be right the first time. Professional repair services must deliver proper diagnostics and solutions to ensure this happens.

Convenience and Reliability: Families are busy, so ease is essential. Reliable scheduling, transparent pricing, and quality repairs are among the characteristics customers seek in a repair service.

For greater detail on evolving customer expectations, check out Harvard Business Review.

The role played by emergency repair services.

Of the variety of appliance repair services, the need for emergency refrigerator repair services has become more evident.

Rapid Response: You can be sure that, with this ability to offer emergency repair service, outbound technicians are dispatched quickly in response to urgent problems. This minimizes associated downtime and possible food spoilage for residential and commercial clients.

Expert Technicians: Highly qualified technicians will be required for the emergency repair services who can diagnose the fault and repair it without wasting time. Such professionals shall be equipped with the proper tools and expertise to tackle any problem.

Customer Trust: Emergency fix services instill trust within customers. Customers will be more satisfied and loyal to the company if they feel they can count on them in time of need.

The Future of Appliance Repair Services in Quebec

In the future, in Quebec, professional appliance services will increase in demand. Under any circumstances characterizing this new profile, service providers that adapt themselves vis-à-vis market trends and meet customer expectations will succeed.

Training and Certification: There will be a need to ensure continuous training and certification of technicians in new technologies. This enables them to handle different appliances and stay ahead of industrial changes.

Customer-Centric Approach: Focusing on customer satisfaction through reliable, convenient, and high-quality services will remain a priority. Building strong relationships with clients and offering tailored solutions will drive long-term success.

Sustainability Initiatives: Touting green repair practices and the environmental boon of fixing appliances rather than replacing them has broad appeal to environmentally conscious consumers.

For more on the future of appliance repair services, read about it in The New York Times.

Final Thoughts

Outlined herein is the increasing demand for professional appliance repair in Quebec, buttoning the need to stay at the forefront of market trends and changing consumer demand.

With these limitless potentials for emergency fridge repair or any such solution, this sector will graph upwards limitlessly. On the other hand, companies will be assured of meeting such needs when they remain focused on quality, convenience, and sustainability.

Media Contact
Company Name: CAPITAL APPLIANCE REPAIR
Contact Person: Liam
Email: Send Email
Country: Canada
Website: https://capitalappliancerepairqc.ca/

The Boulder Group Arranges Sale of Net Leased Subway property in Michigan

Randy Blankstein and Jimmy Goodman of The Boulder Group represented both sides in the transaction.

The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Subway located at 9350 Telegraph Road in Redford, Michigan for $550,000.

The 1,680 square-foot building benefits from its location along Telegraph Road which experiences over 64,000 vehicles per day. The property shadow anchors Redford Plaza Shopping Mall. Tenants occupying the center include Dollar Tree, Foot Locker, AutoZone, Burlington, GNC, and Octapharma Plasma. Other neighboring retailers include ALDI, Ford, Starbucks, Dunkin’, and Walgreens. Additionally, the property is located less than 20 minutes west of downtown Detroit. There are 350,000+ people living within a five mile radius that earn an average household income of $75,608.

Randy Blankstein and Jimmy Goodman of The Boulder Group represented both sides in the transaction. The seller was a private real estate firm based in California. The buyer was a local investor.

The tenant has been successfully operating at this location since 2008. The lease is absolute triple net with no landlord responsibilities. Subway is a globally recognized fast-food restaurant chain specializing in submarine sandwiches (subs) and salads. Founded in 1965 by Fred DeLuca and Dr. Peter Buck, Subway is renowned for its customizable sandwiches. With over 37,000 locations in more than 100 countries, Subway has become a popular choice for quick, convenient, and personalized meals.

“The corporate guaranty and low absolute rent provided solid fundamentals for potential investors.” said Randy Blankstein, President of The Boulder Group.  Jimmy Goodman of The Boulder Group, added, “The low price-point of this deal generated over a dozen offers despite the current market conditions.”

About The Boulder Group

The Boulder Group is a boutique investment real estate service firm specializing in single tenant net lease properties. The firm provides a full range of brokerage, advisory, and financing services nationwide to a substantial and diversified client base, which includes high-net-worth individuals, developers, REITs, partnerships and institutional investment funds. Founded in 1997, the firm has arranged the acquisition and disposition of over $9 billion of single tenant net lease real estate transactions. From 2013-2024, the firm was ranked in the top 10 companies in the nation for single tenant retail transactions by both Real Capital Analytics and CoStar. The Boulder Group is headquartered in suburban Chicago and has an office in Denver.

More info: www.bouldergroup.com

Media Contact
Company Name: The Boulder Group
Contact Person: Randy Blankstein
Email: Send Email
Phone: 8478816388
Address:3520 Lake Avenue Suite 203
City: Wilmette
State: Illinois
Country: United States
Website: https://www.bouldergroup.com/NNN-Properties-For-Sale.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Boulder Group Arranges Sale of Net Leased Subway property in Michigan

Boosting Property Value with Well-Maintained Appliances

Today, in an exceedingly aggressive real estate market, every minute detail creates a difference in property value and buyer appeal. One thing usually overlooked in this process is the status of the appliances around the household. Residential appliance repair expertise can help home sellers ensure all of their appliances are top-notch, greatly enhancing their home’s appeal and value. Let’s explore how well-maintained appliances can create a difference, supported by case studies and testimonials.

The Effect of Well-Maintained Appliances

Well-maintained appliances not only enhance the functionality but also the aesthetic appeal and energy efficiency of the house as a whole. To this end, most buyers seeking to acquire this category of property will try to avoid those requiring minimal immediate investment in terms of repairs and upgrades, thus, the condition of appliances often becomes a critical consideration factor among these buyers.

Aesthetic Appeal: Shiny, well-maintained appliances in a kitchen or laundry room add an up-to-date look and feel to it. They tell potential buyers the home has been well cared for, which can be among significant selling points.

Energy Efficiency: Most modern appliances have become more energy-efficient, and nearly all are well-maintained—an equally important selling point to most environmentally sensitive homebuyers, mainly to reduce utility expenses. Energy-efficient appliances help lower the carbon footprint of a house.

For more details on the energy-efficient appliances’ benefits, please refer to Energy Star.

Case Study: Selling the Johnson Family Home

The Johnson family recently decided to sell their home in a competitive market. Knowing that the kitchen is often the heart of the house, they invested in residential appliance repair expertise to put their appliances in top condition. All appliances, from the stove and refrigerator to the dishwasher, were inspected and serviced for optimal working order.

The result? In just days of listing, their home received numerous offers well over the asking price. Many prospective buyers remarked about the fact that renovation wasn’t needed in this kitchen at all, part of which could be attributed to their interest in these very well-maintained appliances.

Testimonial from the Johnson Family: “We were thrilled with how quickly our home sold. It paid off to invest in appliance repair, and it helped us get more money for sure.”

Increased Lifespan and Reliability

Properly serviced appliances also last much longer and are generally more reliable. Thus, they will also be very appealing to buyers who want to purchase a house that will not require them to replace expensive appliances anytime soon.

Reliability and Piece of Mind: The professionally maintained appliances put the buyer’s mind at rest. Reduces the possibility of sudden breakdowns or expensive repairs—one of the main deterrents in home buying.

Testimonials: Actual Experiences Told by Actual Clients.

Jane Thompson shares her experience: “We decided to put our house on the real estate market, and, of course, our real estate agent recommended that all our appliances be in perfect working order. That’s when we called in some experts in residential appliance repair; it made a difference. The buyers said they were impressed with the state of our kitchen and laundry room.”

Testimonial from Mark and Lisa Peterson: “We listed our home feeling confident that our appliances had been professionally serviced. This house sold within a very short period, which we highly believe was because the appliances were well-maintained. The buyers just liked knowing that someone had cared for all the appliances and felt more assured with their buy.”

Final Thoughts

Any homeowner who intends to sell their property will be well-advised in residential appliance repair for better value over the long term. Well-maintained appliances do wonders for the aesthetic and functional appeal of your home; besides, they give a sense of reliability and reasonable care to the buyers.

By keeping appliances in top working order, owners will significantly improve the salability of their homes, selling their homes more quickly and for more money. Properly maintaining your appliances is not just about keeping everything running smoothly; it is also about retaining the complete value and appeal of the house. Indeed, don’t overlook this critical aspect when making your home ready for sale.

Media Contact
Company Name: ASAP Appliance Repair
Contact Person: Bob
Email: Send Email
Country: Canada
Website: https://asapservice.ca/

Artificial Turf Market Size, Growth Analysis, Opportunities, Trends, Key Segmentation, Regional Analysis, Top Manufacturers and Forecast to 2028

“Browse 156 market data Tables and 47 Figures spread through 196 Pages and in-depth TOC on “Artificial Turf Market””
The Artificial Turf Market is growing due to increased demand for low-maintenance, durable, and eco-friendly landscaping solutions. Key sectors include sports fields and residential lawns, with North America leading in market share.

The Artificial turf market is estimated at USD 76.6 billion in 2022 and is projected to reach USD 114.3 billion by 2028, at a CAGR of 6.5% from 2023 to 2028. The growing demand for artificial turf in a variety of end-use industries, such as building & construction, automotive, artificial grass, is the main driver of this market expansion. 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121486580  

Based on the end-use industry, the market has been divided into several industries, such as building & construction, automotive, artificial grass, and others. The building & construction industry is predicted to dominate these sectors in the global artificial turf market. This dominance is explained by its contribution to improving the appearance, looks and features of residential and commercial spaces. The applications of artificial turf in the residential sector cover installations in new residential buildings, and renovations. The use of carpets on floors enhances the esthetic appeal and provides comfort. Carpets help the user achieve dynamic control over noise and provide comfort as well as safe and slope-resistant floors. 

Based on the material type, the artificial turf market is segmented into groups like nylon, polypropylene, polyethylene, hybrid and others. Nylon was the first type of fiber used to create artificial turf. Its excellent strength and superior resilient properties make it an ideal choice for artificial grass manufacturers. It will not change its shape even when used rigorously. It is about 33% stronger than polyethylene and 26% stronger than polypropylene. It is the most expensive form of fiber when compared to polypropylene and polyethylene. 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121486580 

Based on the filament type, the artificial turf market is segmented into monofilament and multi-filament. Multi-filament fibers in artificial turf are made up of multiple strands of fiber that are twisted together. They are softer and more flexible than monofilament fibers, making them a good choice for playgrounds and other areas where a softer surface is desired. The demand for monofilament is expected to rise in the sports sector during the forecast period. Multi-filament artificial grass is a robust and versatile synthetic turf variety characterized by fibers composed of bundled smaller filaments, often made from materials like polyethylene, polypropylene, or nylon. This type of artificial grass is prized for its exceptional durability and resilience, making it a preferred choice for demanding applications such as sports fields. 

Based on region, From 2023 to 2028, the artificial turf market is projected to grow with the highest compound annual growth rate (CAGR) in the Asia Pacific region. China accounted for the largest market share of the Asia Pacific artificial turf market in 2022. This significance can be attributed to China’s strong industrial development and ongoing economic landscape improvement. Because 60% of the world’s population lives in the Asia-Pacific region, artificial turf is widely used in a variety of end-use sectors, including building & construction, automotive, artificial grass. 

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121486580 

Major players operating in the artificial turf market include DuPont (US), FieldTurf (Canada), Shaw Industries Group, Inc. (US), ACT Global (US), TigerTurf (US), Mohawk Industries, Inc. (US), Tarkett (France), Lowe’s Companies, Inc. (US), Interface, Inc. (US), Dixie Group, Inc. (US), Oriental Weavers (Egypt), Tai Ping Carpets International Limited (Hong Kong), Victoria PLC (UK), The Home Depot, Inc, (US). These companies have their reliable manufacturing plants and well-established distribution networks that reach across key areas like North America, Europe, and the Asia Pacific. They have a well-known range of top-notch goods and services, a commanding market presence, and solid business plans. Additionally, these businesses control a sizeable portion of the market, provide goods with a variety of uses, serve a large geographic area, and maintain a vast variety of items.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/artificial-turf-market-121486580.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Artificial Turf Market Size, Growth Analysis, Opportunities, Trends, Key Segmentation, Regional Analysis, Top Manufacturers and Forecast to 2028

Cosmetic Antioxidants Market Size, Opportunities, Growth, Trends, Regional Insights, Key Segments, Top Companies and Forecast to 2028

“Browse 346 market data Tables and 56 Figures spread through 287 Pages and in-depth TOC on “Cosmetic Antioxidants Market””
The Cosmetic Antioxidants Market is expanding rapidly, driven by rising consumer demand for skincare and haircare products with anti-aging benefits. Key antioxidants like Vitamin E and Vitamin C dominate, catering to a growing preference for natural and sustainable ingredients globally. North America and Europe lead in market share, driven by strong consumer awareness and product innovation.

In terms of value, the cosmetic antioxidants market is estimated to grow from USD 132 million in 2023 to USD 178 million by 2028, at a CAGR of 6.2%. Cosmetic antioxidants are important in cosmetic formulation and play a key role in encountering free radicals that damage skin and hair. Antioxidants used in cosmetics are substances made of vitamins, enzymes, polyphenols, and minerals. Cosmetic antioxidants are useful in preventing the degradation of ingredients in cosmetic products, skin recovery from damage, UV protection, and slowing down the aging process.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144119844  

The global cosmetic antioxidants market is segmented based on application into skin care, hair care, and make-up. Based on application, the skin care segment was the chief consumer of cosmetic antioxidants in 2022, owing to the high demand for cosmetic antioxidants in anti-aging formulations. The growing demand for cosmetic products, such as anti-aging creams, anti-wrinkle creams, and sunscreens, particularly in emerging countries, has increased the demand for cosmetic antioxidants in the skin care segment of the cosmetic antioxidants market.

Based on source, the cosmetic antioxidants market is segmented into natural and synthetic. Based on source, the natural segment accounted for the major share of the cosmetic antioxidants market in 2022, in terms of value, as the acceptance of natural antioxidants in cosmetic products is increasing owing to their minimal side effects.

The global cosmetic antioxidants market is segmented based on type into vitamins, carotenoids, polyphenols, enzymes, and synthetics. Based on type, the vitamins segment in 2022 led the cosmetic antioxidants market in terms of value. Various types of vitamins and their compounds, such as vitamin E (tocopherols), vitamin C (ascorbic acid), and vitamin A (retinol), are widely used in cosmetic products for moisturizing and nourishment purposes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=144119844 

Based on function, the cosmetic antioxidants market is segmented into anti-aging, anti-inflammatory, UV protection, moisturizing, hair cleansing, hair conditioning, and others. The anti-aging segment led the function segment in 2022. Anti-aging cosmetic products help reduce the appearance of fine lines and pigment evening and provide a smooth skin texture. These products require cosmetic ingredients, such as vitamin A, biotin, coenzyme Q10, glycolic acid, green tea, and other vitamins, that help reduce signs of aging. 

Among the various regions, Asia Pacific accounted for the largest share of the cosmetic antioxidants market in 2022. This region has a extensive base of youth population that spends more on skincare and other cosmetic products. In addition, countries in Asia Pacific region more lenient towards imposing regulations with respect to cosmetic ingredients. Countries such as China and India are thickly populated economies with increasing preference over beauty &  personal care products.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=144119844 

The key players in cosmetic antioxidants market are Evonik Industries AG (Germany), Croda International Plc (UK), BASF SE (Germany), Eastman Chemical Company (US), and Wacker Chemie AG (Germany) are the leading providers of cosmetic antioxidants globally. These companies have manufacturing facilities as well as dominant distribution networks across key regions, such as Asia Pacific, North America, and Europe.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cosmetic-antioxidant-market-144119844.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cosmetic Antioxidants Market Size, Opportunities, Growth, Trends, Regional Insights, Key Segments, Top Companies and Forecast to 2028

Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Hepatic Tumor Pipeline Insight 2024”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Hepatic Tumor Research. Learn more about our innovative pipeline today! @ Hepatic Tumor Pipeline Outlook

Key Takeaways from the Hepatic Tumor Pipeline Report

  • June 2024:- Hoffmann-La Roche- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver). This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
  • June 2024:- AstraZeneca- A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA. A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
  • DelveInsight’s Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
  • The leading Hepatic Tumor Companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
  • Promising Hepatic Tumor Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab, and others.

Stay informed about the cutting-edge advancements in Hepatic Tumor Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatic Tumor Clinical Trials Assessment

Hepatic Tumor Emerging Drugs Profile

  • Namodenoson: Can Fite Biopharma

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer(hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.

  • MTL CEBPA : MiNA Therapeutics

MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.

  • Amivantamab: Janssen Research & Development, LLC

Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.

  • Fostroxacitabine bralpamide: Medivir AB

Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.

  • ETN101: Etnova Therapeutics Corp.

ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.

Learn more about Hepatic Tumor Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatic Tumor Unmet Needs

Hepatic Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

Hepatic Tumor Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Hepatic Tumor Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatic Tumor Market Drivers and Barriers, and Future Perspectives

Scope of the Hepatic Tumor Pipeline Report

  • Coverage- Global
  • Hepatic Tumor Companies- Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
  • Hepatic Tumor Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab, and others.
  • Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Hepatic Tumor Pipeline on our website @ Hepatic Tumor Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatic Tumor: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. Namodenoson: Can Fite Biopharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MTL CEBPA : MiNA Therapeutics
  12. Early Stage Products (Phase I)
  13. Comparative Analysis
  14. ETN101: Etnova Therapeutics Corp.
  15. Inactive Products
  16. Hepatic Tumor Key Companies
  17. Hepatic Tumor Key Products
  18. Hepatic Tumor – Unmet Needs
  19. Hepatic Tumor – Market Drivers and Barriers
  20. Hepatic Tumor – Future Perspectives and Conclusion
  21. Hepatic Tumor Analyst Views
  22. Hepatic Tumor Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Biliary Tumor Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Biliary Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Biliary Tumor Research. Learn more about our innovative pipeline today! @ Biliary Tumor Pipeline Outlook

Key Takeaways from the Biliary Tumor Pipeline Report

  • June 2024:- AstraZeneca- A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers. This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator’s choice of 3 different gemcitabine-based chemotherapy regimens in participants with aBTC with a WHO/ECOG PS of 0 to 2 at enrolment.
  • June 2024:- UNICANCER- Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial. The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
  • DelveInsight’s Biliary Tumor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Biliary Tumor treatment.
  • The leading Biliary Tumor Companies such as Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited, and others.
  • Promising Biliary Tumor Therapies such as Durvalumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine & Cisplatin, KN035, XmAb20717, ZW25 (Zanidatamab), and others.

Stay informed about the cutting-edge advancements in Biliary Tumor Treatments. Download for updates and be a part of the revolution in cancer care @ Biliary Tumor Clinical Trials Assessment

Biliary Tumor Emerging Drugs Profile

  • Rilvegostomig: AstraZeneca

Rilvegostomig (formerly AZD2936) is a bispecific antibody developed by AstraZeneca, targeting both PD-1 and TIGIT to enhance immune responses against cancer. Derived from Compugen’s COM902 antibody, it aims to maximize the blockade of these pathways through cooperative binding, potentially improving therapeutic outcomes. Scheduled to progress into Phase III trials for indications like Biliary cancer, non-small cell lung cancer and gastric cancer, rilvegostomig is also being evaluated in combination with AstraZeneca’s antibody-drug conjugates such as Enhertu, Dato-DXd, and AZD0901, as part of a strategy to leverage its differentiated bispecific format for greater efficacy.

  • SHR-A1811: Jiangsu HengRui Medicine

SHR-A1811 is an antibody-drug conjugate (ADC) composed of trastuzumab, a cleavable linker, and a novel topoisomerase I inhibitor payload called SHR169265. It targets HER2-expressing tumor cells, delivering the cytotoxic payload upon internalization. Once inside the cell, the linker is cleaved, releasing SHR169265 which inhibits topoisomerase I, an essential enzyme for DNA replication and transcription, leading to cell cycle arrest and apoptosis. SHR-A1811 has shown promising antitumor activity in preclinical models and is currently being evaluated in multiple phase I-III clinical trials for HER2-positive and HER2-low breast cancer, gastric cancer, and other solid tumors. Currently, the drug is in Phase II stage of its clinical trial for the treatment of biliary cancer.

  • AMG 193: Amgen

AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of biliary cancer.

Learn more about Biliary Tumor Drugs opportunities in our groundbreaking Biliary Tumor Research and development projects @ Biliary Tumor Unmet Needs

Biliary Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Biliary Tumor Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Biliary Tumor Market Drivers and Barriers, and Future Perspectives

Scope of the Biliary Tumor Pipeline Report

  • Coverage- Global
  • Biliary Tumor Companies- Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited, and others.
  • Biliary Tumor Therapies- Durvalumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine & Cisplatin, KN035, XmAb20717, ZW25 (Zanidatamab), and others.
  • Biliary Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Biliary Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Biliary Tumor Biliary Tumor Pipeline on our website @ Biliary Tumor Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Biliary Tumor: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Biliary Tumor– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Rilvegostomig: AstraZeneca
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SHR-A1811: Jiangsu HengRui Medicine
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AMG 193: Amgen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Biliary Tumor Key Companies
  21. Biliary Tumor Key Products
  22. Biliary Tumor- Unmet Needs
  23. Biliary Tumor- Market Drivers and Barriers
  24. Biliary Tumor- Future Perspectives and Conclusion
  25. Biliary Tumor Analyst Views
  26. Biliary Tumor Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the PD-1 Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1 Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in PD-1 Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ PD-1 Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report

  • June 2024:- Merck Sharp & Dohme LLC- A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer.
  • June 2024:- AstraZeneca- An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON). This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
  • DelveInsight’s PD-1 Non-Small Cell Lung Cancer pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer treatment.
  • The leading PD-1 Non-Small Cell Lung Cancer Companies such as Novartis Pharmaceuticals, Merck Sharp & Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo, Inc., Arcus Biosciences, Inc., IO Biotech, and Cellular Biomedicine Group, Inc., and others.
  • Promising PD-1 Non-Small Cell Lung Cancer Therapies such as Durvalumab, AZD9150, AZD6738, REGN2810, Ipilimumab, Cemiplimab, and others.

Stay informed about the cutting-edge advancements in PD-1 Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ PD-1 Non-Small Cell Lung Cancer Clinical Trials Assessment

PD-1 Non-Small Cell Lung Cancer Emerging Drugs Profile

  • Tislelizumab (BGB-A317) – BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. stigated in the Phase III stage of development for the treatment of PD-1 Non-Small Cell Lung Cancer.

  • Canakinumab: Novartis Pharmarmaceutical

Canakinumab (ACZ885, Ilaris) is a human anti-IL-1β monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of 1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. Currently the driug is in phase III stage of development for the treatment of Non-Small Cell Lung Cancer.

  • PLB-1004: Avistone Biotechnology

Avistone Biotechnology is developing PLB-1004, an oral EGFR inhibitor being studied in patients with non-small cell lung cancer. In December 2021, Avistone Pharmaceuticals, a clinical-stage biotechnology company focused on precision oncology therapeutics, announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital. The investment will support the combination of Avistone with Pearl Biotechnology Co. Ltd. to create a fully-integrated targeted oncology platform that will address unmet patient needs globally. Based in Beijing, China, Avistone has been committed to the development of precision oncology therapeutics for nearly a decade and has a broad oncology pipeline focused on treatments for lung cancer. The Company’s most advanced asset is a c-Met inhibitor in late-stage clinical development for genetically-defined populations of non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Learn more about PD-1 Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking PD-1 Non-Small Cell Lung Cancer Research and development projects @ PD-1 Non-Small Cell Lung Cancer Unmet Needs

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Discover the latest advancements in PD-1 Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • PD-1 Non-Small Cell Lung Cancer Companies- Novartis Pharmaceuticals, Merck Sharp & Dohme, Navire Pharma Inc., AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo, Inc., Arcus Biosciences, Inc., IO Biotech, and Cellular Biomedicine Group, Inc., and others.
  • PD-1 Non-Small Cell Lung Cancer Therapies- Durvalumab, AZD9150, AZD6738, REGN2810, Ipilimumab, Cemiplimab, and others.
  • PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of PD-1 Non-Small Cell Lung Cancer Pipeline on our website @ PD-1 Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. PD-1 Non-Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. PD-1 Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Canakinumab: Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MK-5890: Merck Sharp & Dohme
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. BBP-398: Navire Pharma Inc.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. PD-1 Non-Small Cell Lung Cancer Key Companies
  21. PD-1 Non-Small Cell Lung Cancer Key Products
  22. PD-1 Non-Small Cell Lung Cancer- Unmet Needs
  23. PD-1 Non-Small Cell Lung Cancer- Market Drivers and Barriers
  24. PD-1 Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
  25. PD-1 Non-Small Cell Lung Cancer Analyst Views
  26. PD-1 Non-Small Cell Lung Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PD-1 Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Peritoneal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Peritoneal Cancer Pipeline Insight 2024” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the Peritoneal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peritoneal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Peritoneal Cancer Research. Learn more about our innovative pipeline today! @ Peritoneal Cancer Pipeline Outlook

Key Takeaways from the Peritoneal Cancer Pipeline Report

  • June 2024:- ImmunoGen Inc.- Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)
  • June 2024:- Tesaro Inc.- A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
  • June 2024:- K-Group, Beta, Inc.- A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI).
  • DelveInsight’s Peritoneal Cancer pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Peritoneal Cancer treatment.
  • The leading Peritoneal Cancer companies such as Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others.
  • Promising Peritoneal Cancer Therapies such as Bevacizumab, 131 I-omburtamab, Catumaxomab, Fulvestrant, Abemaciclib, Mirvetuximab soravtansine plus Bevacizumab, Pembrolizumab, MORAb-202, KAND567, and others.

Stay informed about the cutting-edge advancements in Peritoneal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Peritoneal Cancer Clinical Trials Assessment

Peritoneal Cancer Emerging Drugs Profile

  • Masitinib: AB Science

Masitinib is an orally administered tyrosine kinase inhibitor. It modulates the activity of mast cells and macrophages, important cells for immunity, through targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Masitinib’s mechanism of action in peritoneal cancer involves inhibiting tumor growth by targeting specific kinases like KIT and PDGFR, crucial for cancer progression, without causing general toxicity. Currently, the drug is in Phase III stage of its clinical trial for the treatment of peritoneal cancer.

  • Azenosertib: Zentalis Pharmaceuticals

Azenosertib is a potentially first-in-class and best-in-class small molecule Wee1 inhibitor in development for the treatment of cancer. Inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved WEE1 inhibitors, and we have designed Azenosertib to have advantages over other investigational therapies, including superior selectivity and pharmacokinetic properties. Currently, the drug is in Phase II stage of its clinical trial for the treatment of peritoneal cancer.

  • IMGN151: ImmunoGen

IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). IMGN151 comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FRα, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. Currently, the drug is in Phase I stage of its clinical trial for the treatment of peritoneal cancer.

Learn more about Peritoneal Cancer Drugs opportunities in our groundbreaking Peritoneal Cancer Research and development projects @ Peritoneal Cancer Unmet Needs

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Peritoneal Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Peritoneal Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Peritoneal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Peritoneal Cancer Pipeline Report

  • Coverage- Global
  • Peritoneal Cancer companies- Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others.
  • Peritoneal Cancer Therapies- Bevacizumab, 131 I-omburtamab, Catumaxomab, Fulvestrant, Abemaciclib, Mirvetuximab soravtansine plus Bevacizumab, Pembrolizumab, MORAb-202, KAND567, and others.
  • Peritoneal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Peritoneal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Peritoneal Cancer Pipeline on our website @ Peritoneal Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Peritoneal cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Peritoneal cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Masitinib: AB Science
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Azenosertib: Zentalis Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. IMGN151: ImmunoGen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Peritoneal cancer Key Companies
  21. Peritoneal cancer Key Products
  22. Peritoneal cancer- Unmet Needs
  23. Peritoneal cancer- Market Drivers and Barriers
  24. Peritoneal cancer- Future Perspectives and Conclusion
  25. Peritoneal cancer Analyst Views
  26. Peritoneal cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peritoneal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight